ABSTRACT X-linked congenital nephrogenic diabetes insipidus (cNDI) results from inactivating mutations of the human arginine vasopressin (AVP) V2 receptor (hV 2 R). Most of these mutations lead to intracellular retention of the hV 2 R, preventing its interaction with AVP and thereby limiting water reabsorption and concentration of urine. Because the majority of cNDI-hV 2 Rs exhibit protein misfolding, molecular chaperones hold promise as therapeutic agents; therefore, we sought to identify pharmacochaperones for hV 2 R that also acted as agonists. Here, we describe high-affinity nonpeptide compounds that promoted maturation and membrane rescue of L44P, A294P, and R337X cNDI mutants and restored a functional AVP-dependent cAMP signal. Contrary to pharmacochaperone antagonists, these compounds directly activated a cAMP signal upon binding to several cNDI mutants. In addition, these molecules displayed original functionally selective properties (biased agonism) toward the hV 2 R, being unable to recruit arrestin, trigger receptor internalization, or stimulate mitogen-activated protein kinases. These characteristics make these hV 2 R agonist pharmacochaperones promising therapeutic candidates for cNDI. The antidiuretic hormone arginine-vasopressin (AVP) is crucial for osmoregulation, cardiovascular control, and water homeostasis. The human AVP V 2 receptor (hV 2 R), localized in the principal cells of the kidney collecting duct, mediates AVP antidiuretic effect and therefore helps in maintaining physiologic plasma osmolality, blood volume, and arterial pressure. Binding of AVP to hV 2 R first triggers a cAMP signal through activation of the G protein ␣ s (Gs) subunit and adenylyl cyclase (AC). Then, the cAMP-activated protein kinase A phosphorylates aquaporin 2 water channels, resulting in their insertion into the luminal membrane of principal cells and finally to water reabsorption. 1 AVP binding to hV 2 R also induces arrestin recruitment, receptor internalization, 2 and mitogen-activated protein kinase (MAPK) activation. 3 Mutations in the hV 2 R gene lead to the X-linked congenital nephrogenic diabetes insipidus (cNDI), a rare disease characterized by the kidney's inability to concentrate urine despite normal or elevated plasma concentrations of AVP. 4 More than 200 different mutations have been described and are responsible for polyuria, a main consequence of the disease. Most of the mutant receptors (cNDIhV 2 Rs), trapped in the endoplasmic reticulum
The antidiuretic hormone arginine-vasopressin (AVP) is crucial for osmoregulation, cardiovascular control, and water homeostasis. The human AVP V 2 receptor (hV 2 R), localized in the principal cells of the kidney collecting duct, mediates AVP antidiuretic effect and therefore helps in maintaining physiologic plasma osmolality, blood volume, and arterial pressure. Binding of AVP to hV 2 R first triggers a cAMP signal through activation of the G protein ␣ s (Gs) subunit and adenylyl cyclase (AC). Then, the cAMP-activated protein kinase A phosphorylates aquaporin 2 water channels, resulting in their insertion into the luminal membrane of principal cells and finally to water reabsorption. 1 AVP binding to hV 2 R also induces arrestin recruitment, receptor internalization, 2 and mitogen-activated protein kinase (MAPK) activation. 3 Mutations in the hV 2 R gene lead to the X-linked congenital nephrogenic diabetes insipidus (cNDI), a rare disease characterized by the kidney's inability to concentrate urine despite normal or elevated plasma concentrations of AVP. 4 More than 200 different mutations have been described and are responsible for polyuria, a main consequence of the disease. Most of the mutant receptors (cNDIhV 2 Rs), trapped in the endoplasmic reticulum (ER), cannot reach the cell surface and interact with AVP. 5 cNDI is thus referred as a conformational or protein-misfolding disease. 6 Various chaperones, 7 either chemical (cellular osmolytes such as glycerol or DMSO) or pharmacologic (specific ligands), 8, 9 are promising therapeutic agents for future clinical treatment of protein-misfolding disorders. Because a majority of cNDI-hV 2 Rs are misfolded and many ligands are available for hV 2 R, the pharmacochaperone-based strategy is of particular interest for cNDI. Considering an efficient therapy for this disease, the ideal drug should combine pharmacochaperone properties together with hV 2 R agonist and noninternalizing activities, for stimulating AC and maintaining a long-lasting cAMP signal. This would classify such a molecule as a biased agonist or functionally selective compound. 10 Small nonpeptide AVP antagonists (commonly named vaptans)-such as the hV 2 R-selective antagonists SR121463 (satavaptan), VPA985 (lixivaptan), 11 OPC41061 (tolpavtan), and OPC31260 (mozavaptan) 12 ; the V 1a receptor (V 1a R) antagonist SR49059 (relcovaptan); and the nonselective V 1a R/ V 2 R antagonist YM087 (conivaptan) 13 -were demonstrated to promote adequate maturation and cell surface rescue of cNDI-hV 2 response upon AVP binding. Although the vaptans display the expected pharmacochaperone beneficial effects, their antagonistic activity limits their use as a result of their inability to stimulate membrane-targeted cNDI-hV 2 Rs directly. Comparatively, agonist pharmacochaperones would combine crucial advantages for treating cNDI.
Here, we identified the first functionally selective hV 2 R agonist pharmacochaperones. The Wyeth-Ayerst WAY-VNA-932 and the Otsuka OPC23h nonpeptide hV 2 R antidiuretics, 14, 15 as well as a novel compound MCF57, were tested for their capacity to recruit intracellularly trapped cNDI-hV 2 Rs and to restore their functionality. In addition, we determined the capacity of the three ligands to act as hV 2 R biased agonists (i.e., their behavior in terms of Gs/AC agonism and arrestin antagonism).
RESULTS

Nonpeptide Compounds Have a High Affinity for hV 2 R and Induce Receptor-Dependent cAMP Production
To develop ligands exhibiting both hV 2 R agonist properties and pharmacochaperone effects on cNDI-hV 2 Rs, we used the Otsuka OPC23h and the Wyeth-Ayerst WAY-VNA-932 nonpeptide hV 2 R agonist molecules as lead compounds. New molecules derived from these antidiuretics were synthesized for optimizing preferential affinity and activity toward hV 2 R. The pharmacologic properties of one of these hits, MCF57 ( Figure  1A ), were compared with those of OPC23h (termed MCF14 here) and WAY-VNA-932 (named MCF18) in terms of hV 2 R affinity and Gs/AC activation. The three ligands fully displaced H]AVP binding to the hV 1b R. They all displayed a preferential affinity (6 to 20 nM) for the c-myc-hV 2 R versus other receptor subtypes (Table 1) . MCF57 possessed the best hV 2 R selectivity index. Determination of agonist properties of the nonpeptide compounds for the c-myc-tagged hV 2 R using cAMP accumulation as a readout. The tsA201 cells transfected with the c-mychV 2 R were incubated for 30 min at 37ЊC in a cAMP buffer containing 0.1 mM RO 201724 with or without increasing amounts of AVP (F), MCF57 (E), MCF14 (‚), or MCF18 (f). As described in the Concise Methods section, cAMP accumulation was evaluated using the Cisbio International Dynamic 2 kit based on fluorescence resonance energy transfer measurements. Basal cAMP accumulation values were subtracted from values obtained with AVP or MCFs. Data are means Ϯ SEM of cAMP concentration (nM). The figure illustrates an experiment representative of three distinct experiments, each performed in triplicate. Binding assays were performed as described in the Concise Methods section and are illustrated in Figure 2 . ͓ 3 H͔AVP binding was measured on whole tsA201 cells transfected with c-myc-hV 2 R, c-myc-hV 1a R, c-myc-hV 1b R, or c-myc-hOTR subtypes and displaced using increasing concentrations of AVP, MCF14, MCF18, or MCF57. Inhibition constants (K i in nM) were determined from the competition experiments performed using ͓ 3 H͔AVP concentrations around K d for the various receptors (i.e., 1.5 nM). Data are means Ϯ SEM of three distinct experiments each done in duplicate. 
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We characterized the agonist properties of the three MCFs to the c-myc-hV 2 R through their capacity to induce a cAMP accumulation (which correlates to Gs/AC stimulation). The ligands exhibited efficiencies similar to AVP (E max values were close to that for AVP maximal response) but lower potencies (nanomolar EC 50 values), as illustrated by a rightward shift of the dose-response curves ( Figure 3 ; Table 2 ). The three MCFs, however, are full agonists of the hV 2 R regarding the Gs/AC pathway.
Nonpeptide Agonist Compounds Are Pharmacochaperones for Several cNDI-hV 2 Rs
We determined the capacity of MCFs to trigger plasma membrane expression of several cNDI-hV 2 Rs: L44P, 16 L59P, Y128S, A294P, and R337X ( Figure 1B ). 11 These mutants are known to be sequestered mainly either in the ER or in the ER-Golgi intermediate compartment (although Y128S was shown to be partially present at the cell surface 11 ) and functionally rescued by the hV 2 R antagonist SR121463. We also tested the murine V 2 R (mV 2 R), which is predominantly retained within the ER as an immature protein 17 but also membrane-targeted by the vaptans. 18 Treatment of the cells with each MCF led to a significant increase in the L44P, A294P, and R337X membrane expression levels, compared with control cells treated with 0.1% DMSO only ( Figure 4 , A through C). The MCFs were very effective and their rescue properties equivalent to those of the reference pharmacochaperone SR121463. By contrast, whereas SR121463 was still efficient to rescue Y128S and L59P, MCFs were either less active or inactive, respectively ( Figure 4 , D through E). Interestingly, the agonists increased significantly membrane expression of the mV 2 R, such as SR121463 ( Figure  4F ). The three MCFs exhibited similar pharmacochaperone behavior, being active on several receptors (L44P, A294P, and R337X), less active on others (Y128S and mV 2 R), or inactive (L59P).
To avoid potential escape from the cell quality control system as a result of mutant overexpression, we defined conditions in which no cNDI-hV 2 Rs could be detected at the cell surface in control situation using varying plasmid quantities. Even with low cNDI-hV 2 R plasmid quantities, membrane targeting of the intracellularly retained cNDI-hV 2 Rs using MCF57 as a pharmacochaperone reference was evidenced (Supplemental Figure 1) .
We also checked membrane rescue of cNDI-hV 2 Rs by directly visualizing the effects of MCF57 using confocal microscopy. We performed immunofluorescence experiments with nonpermeabilized cells to label only cell surface receptors. L44P, A294P, and R337X were shown to respond efficiently to the pharmacochaperone treatment. Incubation of cells with MCF57 allowed detection of a clear surface labeling that was not seen in control cells treated with DMSO ( Figure 5 ).
Agonist Pharmacochaperones Promote cNDI-hV 2 R Maturation
To evidence maturation of cNDI-hV 2 Rs under MCF treatment, we analyzed the glycosylation pattern of L44P, A294P, and R337X.
In control conditions, the three cNDI-hV 2 Rs were detected only as immature proteins (apparent molecular weight approximately 40 kDa, or 36 kDa for R337X) compared with the complex-glycosylated hV 2 R (apparent molecular weight approximately 50 kDa; Figure 6) . Treatment of the receptors with EndoH deglycosylated cNDI-hV 2 Rs immature forms without effect on the mature hV 2 R forms, indicating that the three cNDI-hV 2 Rs are probably high-mannose glycosylated proteins trapped in the ER. Interestingly, treatment of the cells with the pharmacochaperone MCF14 allowed efficient complex glycosylation of the cNDI-hV 2 Rs, an effect comparable to that of SR121463. This confirmed the ability of MCF compounds to promote maturation and plasma membrane translocation of L44P, A294P, and R337X.
Membrane-Rescued cNDI-hV 2 Rs Are Functional
We checked the functionality of membrane-rescued cNDI-hV 2 Rs by measuring their ability to generate a cAMP response upon AVP stimulation. As in previous studies with antagonist pharmacochaperones, 11, 19, 20 we determined cNDI-hV 2 R activity after washing the cells (elimination of the pharmacochaperone) and subsequently stimulating them with AVP. First, optimal plasmid quantities were determined to avoid cNDI-hV 2 R plasma membrane expression and a cAMP response in control conditions (Supplemental Figure 1) . Then, using an 18-h preincubation with MCF57 concentrations from 30 nM to 10 M, we were able to evidence further the cAMP responses to AVP with different efficiencies for L44P, A294P, and R337X ( Figure 7) . The L44P and A294P mutants were sensitive to AVP after pretreatment with 30 nM MCF57. R337X was sensitive to AVP only when preincubated with 10 M MCF57. An 18-h AVP preincubation had no effect on the cAMP response whatever the cNDIhV 2 R considered, as in control situation, confirming that AVP is not a pharmacochaperone ( Figure 7 ). These data show that rescued L44P, A294P, and R337X are functional once targeted to the plasma membrane using low pharmacochaperone concentrations. The results obtained with MCF57 were reproducible with MCF14 and 18, although statistically less significant, these ligands used at 10 M being more difficult to eliminate, even though extensive washes were performed (data not shown). V2R Biased Agonist Pharmacochaperones specificity of interactions between cNDI-hV 2 Rs and the different pharmacochaperones; therefore, MCF ligands were unable to stimulate R337X ( Figure 8D ).
Nonpeptide Pharmacochaperones Are Antagonists of Arrestin Recruitment
The capacity of the MCF agonists to elicit hV 2 R-arrestin binding was investigated by bioluminescence resonance energy transfer measurements (BRET), using the receptor fused with Luciferase as a donor and ␤-arrestin 1 or 2 fused with the yellow fluorescence protein as an acceptor. Control cells were treated with DMSO 0.1% and stimulated by AVP. MCF14, representative of the three agonists, could not induce ␤-arrestin 1 recruitment ( Figure 9A ) but inhibited AVP-stimulated hV 2 R-arrestin binding ( Figure 9B ). These effects were mimicked by the inverse agonist SR121463 (Figure 9 , C and D), contrasting with what has been published previously. 21 Statistical results of the ␤-arrestin 1 mobilization with each MCF alone or combined with AVP are shown in Figure 9E . MCF18 was unable to mobilize arrestin but inhibited the AVP effect. MCF57 induced a slight increase in arrestin recruitment (Ͻ10% of the AVP response) and inhibited AVP-dependent arrestin mobilization. The effects of MCF14 and SR121463 on arrestin recruitment were identical using ␤-arrestin 2 (Supplemental Figure 2 ). Contrary to AVP, the MCFs exhibited antagonistic effects on hV 2 R-dependent arrestin recruitment. They consequently display functional selectivity properties.
Nonpeptide Pharmacochaperones Are Unable to Induce hV 2 R Internalization
Because arrestins are involved in hV 2 R internalization, we evaluated the capacity of the MCFs potentially to induce this receptor-associated pathway. Indeed, hV 2 R internalization was investigated by ELISA using the N-terminal c-myc tag as a readout to measure disappearance of the receptor from the cell surface upon ligand binding. Neither a 30-min nor a longlasting (18 h) application of the various compounds (MCF14, 18, or 57, 10 M) provoked hV 2 R internalization ( Figure 10 ). The antagonist SR121463 displayed the same behavior. As a positive control, AVP induced a significant hV 2 R internalization for a short or a long incubation period (31 Ϯ 4 and 62 Ϯ 5% of hV 2 R were internalized, respectively). The AVP-induced internalization could be inhibited by 10 M of the various MCF compounds (data not shown). The MCFs are noninternalizing hV 2 R agonists.
Nonpeptide Pharmacochaperones Are Antagonists of the MAPK Signaling Pathway AVP activation of the hV 2 R leads to arrestin recruitment, which in turn behaves as a scaffold protein for MAPK stimulation. 22, 23 MAPK activity can be measured through modifica- tion of the level of extracellular signal-regulated kinase 1 and 2 (ERK1/2) phosphorylation (p-ERK). We evaluated the effect of the MCFs used alone or in combination with AVP on the hV 2 R-dependent MAPK activity ( Figure 11 ). Contrary to AVP, MCF14, 18, and 57 were not able to induce ERK phosphorylation, their effect being not significantly different from the control (cells treated with DMSO). The hV 2 R inverse agonist SR121463 was not able to induce MAPK activation on its own. 21 The MCF compounds were able to inhibit significantly the AVP-induced p-ERK. These results confirmed that MCF14, 18, and 57 are biased agonists.
DISCUSSION
Chemical chaperones, pharmacochaperones, or cell-penetrating peptides have been developed to correct plasma membrane-targeting deficiency of misfolded G protein-coupled receptors (GPCRs). 24, 25 Pharmacochaperones are the most promising candidates because of their target specificity. For instance, the P23H rhodopsin mutant responsible for autosomal dominant retinitis pigmentosa and mutants of the gonadotropin-releasing hormone receptor responsible for hypogonadotropic hypogonadism were rescued by the inverse agonist 9-cis-retinal and an antagonist, respectively. 26, 27 The ␦ opioid receptor, displaying low intrinsic maturation efficiency, was membrane-targeted with selective opioid ligands. 28 Considering AVP receptors, the nonpeptide antagonists SR121463 and VPA985 were first shown to rescue cell surface expression of several cNDI-hV 2 Rs. 11 This effect was reproduced using the AVP antagonists SR49059, 29 YM087, 13 OPC41061, and OPC31260. 12 Because most of the cNDI-hV 2 Rs are functional once targeted to the plasma membrane, a pharmacochaperone-based therapy represents a potential general treatment of the disease. Using antagonists as pharmacochaperones, functional rescue is a subtle balance between the ability of the ligand to target cell surface expression of the cNDI-hV 2 Rs and its possibility to be displaced by AVP for receptor activation. 12 In this regard, considering the antagonist affinity as an important feature for this challenge, either low concentrations of antagonists with high affinity (SR121463) 11, 12 or higher concentrations of nonspecific hV 2 R antagonists with low affinity (SR49059) may be used. 13 Although SR49059 behaved as an efficient pharmacochaperone in patients with cNDI, 13 it revealed hepatic toxicity during phase II of its clinical development. An important al-X X X Figure 12 . Various transduction pathways induced or inhibited by the biased agonist pharmacochaperones. The nonpeptide pharmacochaperone compounds (MCFs) are able to cross the various cellular membranes and interact with intracellularly ER-retained cNDI-hV 2 Rs (step 1), enabling their maturation and translocation to the plasma membrane through the ER-Golgi intermediate compartment (Ergic) and the Golgi systems (step 2). Once the cNDI-hV 2 Rs are at the cell surface, the agonist pharmacochaperones activate the cAMP pathway through interaction between receptors with the Gs protein and stimulation of AC (step 3). Contrary to the hormone AVP, the MCF ligands do not recruit arrestins and are unable to internalize hV 2 Rs and to activate the MAPK pathway (step 4).
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ternative to the antagonists would be the use of agonists able both to restore membrane trafficking of cNDI-hV 2 Rs and to promote their activation directly. These ligands would behave as more beneficial cNDI drugs.
We characterized here some hV 2 R nonpeptide agonists displaying such properties. OPC23h, 15 WAY-VNA-932, 14 and MCF57 have a nanomolar affinity for hV 2 R and behave as full agonists for AC activation. They possess a lower affinity for hV 1a R and hOTR. These molecules do not bind to hV 1b R, in agreement with available data for OPC23h and WAY-VNA-932. 14,15 They membrane-rescued the L44P, Y128S, A294P, and R337X mutants and the mV 2 R but were inactive toward L59P. This suggests that these agonists preferentially rescue some given misfolded cNDIhV 2 Rs, whereas the antagonist pharmacochaperones (SR121463, VPA985, YM087, and SR49059) may have a larger spectrum of efficiency. 11, 30 Efficiency of cNDI-hV 2 R membrane translocation between the various pharmacochaperones could be directly related to the affinity of each ligand for each mutant 12 ; however, the nonpeptide agonists having an hV 2 R relatively high affinity (6 to 20 nM) are unable to rescue L59P, contrary to the low-affinity SR49059 antagonist. 13, 29 Even though pharmacochaperones need to bind to mutants, affinity seems not to be the only critical parameter. The mutation L59P itself may also change the whole structure of the receptor and explain why the agonist cannot interact anymore with the binding site. Finally, different conformational changes induced by agonists rather than antagonists may explain the differences observed in terms of rescuing. 18 Altogether, a more exhaustive series of cNDI-hV 2 Rs should be investigated and several other agonist pharmacochaperones should be developed to rescue a larger panel of cNDI-hV 2 Rs.
In terms of signaling, contrary to the antagonist pharmacochaperones, the MCF compounds directly activated membrane-targeted L44P and A294P cNDI-hV 2 Rs but not the R337X, despite restoration of membrane trafficking. Poor functional recovery of R337X, potentially reflecting an impairment of this mutant in its ligand affinity and/or its ability to interact with Gs, has been previously described. 11 For L44P and A294P mutants, a single molecule having both pharmacochaperone and agonist properties seems highly beneficial and may represent an alternative to antagonists for cNDI treatment.
A drawback of most GPCR agonists regarding long-term efficacy is their propensity to trigger internalization of target receptors, leading to desensitization and decrease in the intensity of cell response. Arrestins are key players regarding desensitization/internalization of GPCRs or MAPK activation. 31 These phenomena were shown to occur upon AVP stimulation of the hV 2 R. 32, 33 In contrast to AVP, MCF compounds were unable to induce arrestin mobilization (both ␤-arrestin 1 and 2). Together with their Gs agonism, they thus displayed functional selectivity properties. Moreover, they could antagonize the strong and long-lasting interaction of hV 2 R with arrestins upon AVP binding. Accordingly, these molecules could not promote hV 2 R internalization and MAPK stimulation, confirming their cAMP selectivity. A schematic view of the transduction pathways induced or inhibited by the pharmacochaperone MCFs after binding to cNDI-hV 2 Rs is shown in Figure  12 . Functional selectivity or biased agonism describes the capacity of ligands to induce selectively one or several pathways among all those usually activated by the endogenous related agonist. 10 It is of major importance for future drug development. Indeed, the -opioid agonist herkinorin activates Gi protein coupling and MAPKs but not arrestin recruitment and receptor internalization. 34 Herkinorin represents a promising opiate analgesic with limited adverse effects such as tolerance. J-2156, a peptidomimetic analogue of somatostatin is a superagonist of the somatostatin receptor 4 subtype but does not cause desensitization. 35 This makes it clinically useful for controlling cellular proliferation in tumorous tissues. The OT antagonist atosiban, which is used clinically for preventing preterm birth, inhibits Gq and concomitantly stimulates Gi, leading to MAPK activation and cell proliferation. 36 The hV 2 R agonist pharmacochaperones, devoid of arrestin recruitment and acting as noninternalizing ligands, seem to be particularly adapted for the treatment of the cNDI, potentially providing a long-lasting cellular response during drug administration.
CONCISE METHODS
Cell Culture and Transfection
Human embryonic kidney HEK293 T cells and the SV40-transformed HEK293 cell line tsA201 were used and transfected as described in the Supplemental Concise Methods. For both types of experiments, the accumulated cAMP was quantified using the cAMP Dynamic 2 Kit from Cisbio Int. (Bagnols-surCèze, France) based on a homogeneous time-resolved fluorescencefluorescence resonance energy transfer technology. 37 The principle of the kit is described in the Supplemental Concise Methods.
ELISA Experiments
TsA201 cells were electroporated as described already with 100 and 250 ng of DNA plasmids coding for N-terminally c-myc-tagged hV 2 R and cNDI receptors, respectively, and seeded at a density of 75 ϫ 10 3 per well in polyornithinilated Greiner 96-well plates. Twenty-four hours after transfection, cells were treated with MCF compounds (10 M in 0.1% DMSO) in serum-free DMEM or with 0.1% DMSO at 37°C. All subsequent steps were done at room temperature. Eighteen hours later, cells were fixed for 5 min with 4% formaldehyde diluted in PBS 1ϫ and then washed with PBS 1ϫ. Cells were blocked for 30 min with PBS 1ϫ containing 1% FCS. Then, anti-c-myc antibody (9E10; 1 g/ml) was added for 30 min. After blocking buffer washes, antimouse horseradish peroxidase (HRP)-coupled secondary antibody (0.55 g/ml) was added for 30 min. After blocking buffer and PBS washes, the Super signal reagent was added and luminescence was recorded using the ANALYST apparatus. The cell surface receptor expression was expressed as a percentage of c-myc-hV 2 R expression (maximal expression) in the same cells.
Immunocytochemistry
TsA201 cells were seeded on polyornithine-precoated glass coverslips at a density of 1.5 ϫ 10 5 cells per 18-mm dish. Twenty-four hours after transfection, the medium was removed and replaced by serum-free medium containing compounds at 10 M in 0.1% DMSO. Control cells were incubated at 37°C in medium containing only 0.1% DMSO. Eighteen hours later, cells were first rinsed once with PBS at room temperature. All subsequent steps were done at room temperature. The cells were fixed for 5 min in 4% paraformaldehyde-PBS and rinsed once rapidly with PBS and twice again with PBS (10 min each time). Then, cells were washed twice with PBS-BSA 1% (blocking buffer) for 10 min and incubated for 2 h with the rabbit anti-c-myc antibody (A14) at 1 g/ml. Then, the cells were washed twice with blocking buffer, and Cy3-labeled secondary anti-rabbit antibody (0.62 10 Ϫ10 g/ml) was added for 1 h. The cells were rinsed twice with PBS and H 2 O. Slides were mounted in Fluomount (Interchim), and images were collected on a Bio-Rad fluorescence confocal microscope.
Immunoprecipitation and Analysis of Glycosylation Pattern of the Receptors
After transfection of the cells with 250 ng of c-myc-tagged L44P, A294P, and R337X or 100 ng of c-myc-hV2R, tsA201 cells were seeded at a density of 15 ϫ 10 6 cells per 150-mm dish with complete medium. Twenty-four hours after transfection, the medium was removed and replaced by serum-free medium without (control conditions containing only 0.1% DMSO) or with either MCF14 or SR121463 at 10 M in 0.1% DMSO. Eighteen hours later, cells were rinsed twice with PBS at 4°C and resuspended into lysis buffer (50 mM Tris-HCl [pH 7.4], 1 mM EDTA, 200 mM NaCl, 1 mM Na 3 VO 4 , 1% Triton X-100, 10 g/ml leupeptin, and 10 g/ml aprotinin) and mixed at 4°C for 30 min. Then the lysate was centrifuged at 21,000 ϫ g to eliminate insoluble cell fragments, and the protein concentration was measured into the supernatant. C-myc antibodies (4 g) were covalently linked to agarose-protein G (50 l) using 20 mM dimethyl-pimelimidate reagent (Sigma-Aldrich, St. Louis, MO). After clearing, protein lysate (1 mg/ml) was incubated overnight at 4°C with the c-myc-coupled agarose beads. Immune complexes were collected by centrifugation and washed twice with washing buffer (50 mM Tris-HCl [pH 7.4], 1 mM EDTA, 0.1% Triton X-100, 1 mM Na 3 VO 4 , 10 g/ml leupeptin, and 10 g/ml aprotinin). The beads were divided into two fractions, and 100 l of washing buffer containing or not 12.5 mU of EndoH was added to the beads and mixed for 3 h at 37°C. Beads were then centrifuged at 10,000 ϫ g, and 100 l of 2ϫ Laemmli was added before Western blotting analysis.
Protein samples (30 l) separated using 12% SDS/PAGE were blotted onto nitrocellulose membranes (Hybond-C; Amersham Biosciences, Buckinghamshire, UK). Nitrocellulose membranes were incubated overnight at 4°C with 5 g/ml c-myc antibodies. HRP-labeled secondary anti-mouse (from sheep) antibodies (Amersham Biosciences) at 0.22 g/ml were then used for primary antibody detection. Immunoreactivity was detected using an enhanced chemiluminescence method according to manufacturer's instructions (ECL detection reagent; Amersham Biosciences).
BRET Measurements
TsA201 cells (5 ϫ 10 6 ) were electroporated with 5 g of DNA: 150 ng of hV 2 R-Rluc and 1 g of ␤-arrestin 1-YFP or 800 ng of hV 2 R-Rluc and 1.8 g of ␤-arrestin 2-YFP and empty vector. A total of 2.5 ϫ 10 6 cells from the electroporation step were subsequently seeded per well of a six-well plate. Forty-eight hours after transfection, the cells were washed twice with KREBS buffer (146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl 2 , 1 mM CaCl 2 , 10 mM HEPES [pH 7.4], and 1 mg/ml glucose) and resuspended in 1 ml of KREBS. BRET measurements were performed into Greiner 96-well plates with a final volume of 50 l using 30 l of cellular suspension corresponding to approximately 75,000 cells with 10 l of the Rluc substrate Coelenterazine-h (final concentration 5 M) and 10 l of KREBS buffer containing 5ϫ DMSO, AVP, MCF, or AVP and MCF mixed together (to determine the antagonist effect on arrestin mobilization). The mix suspension was incubated at 37°C, and BRET measurements were acquired on a BertholdTech Mithras LB940 using the MikroWin software. The BRET signal corresponded to the ratio between the light emitted at 530 nm (EYFP) and the light emitted at 480 nm (RLuc) from cells transfected with V 2 R-Rluc and ␤-arrestin 1-YFP (or ␤-arrestin 2-YFP) corrected for the background signal that corresponds to the same ratio from cells transfected with the receptor alone (V 2 R-Rluc). The BRET net signal was calculated from the difference between the corrected ratio 530 nm/480 nm of agonist-treated cells and vehicletreated cells. All compounds were diluted in KREBS with a final DMSO concentration of 0.1% as in control conditions.
ERK Activation and Immunoblotting
HEK 293T cells stably expressing c-myc-hV 2 R were seeded at the density of 150 ϫ 10 3 in 12-well plates coated with polyornithine into DMEM containing 10% FCS. Approximately 24 h later, cells were treated overnight with serum-free medium. Two hours before ligand stimulation, the medium was replaced with fresh serum-free medium. Cells were then incubated for 3 min at 37°C in serum-free DMEM without (control) or with 10 Ϫ7 M AVP (maximal effect) or 10 Ϫ5 M MCF14, MCF18, MCF57, or AVP and MCF mixed together (antagonist effects). Then, the cells were washed twice with cold PBS 1ϫ and lysed using Laemmli buffer 2ϫ. Protein samples were separated onto 12% SDS/polyacrylamide gels and blotted onto nitrocellulose membranes (Hybond-C; Amersham Pharmacia Biotech). The membranes were incubated overnight at 4°C with rabbit anti-p-ERK1/2 primary antibodies (0.4 g/ml). An anti-rabbit HRP-conjugated antibody (0.1 g/ml) was added to reveal p-ERK. After stripping of the membranes, total ERK proteins were detected by using a concentration of 0.2 g/ml rabbit anti-ERK2 antibodies and anti-rabbit HRP-conjugated secondary antibodies (0.1 g/ml). p-ERK1/2 and ERK2 were visualized using the enhanced chemiluminescence reagent ECL.
Statistical Analysis
Results are reported as group means Ϯ SEM from at least three independent experiments, each performed in duplicate or triplicate. The t test gave us the statistical significance of differences between independent groups with: P Ͻ 0.05, P Ͻ 0.01, and P Ͻ 0.001.
